PLANTATION, Fla., May 23, 2006 (PRIMEZONE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (www.medirectlatino.org), the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community, announced today the Company will participate in Business Mission: China 2006, June 2 - 14, 2006, as an invited delegate for an official visit to the People's Republic of China. The itinerary, with scheduled meetings in Shanghai, Chengdu and Beijing, is coordinated by Broward County Office of Economic Development, The Broward Alliance and certified by Enterprise Florida Inc., the Governor's public private economic development organization.
During the Mission, MEDirect Latino will meet with businesses and private equity funds in China interested in establishing commerce, manufacturing and investment relationships with the Company. MEDirect Latino has been selected as a host company at the U.S. Embassy dinner reception in Beijing and will brief attendees on the Company's strategic initiatives focused on the growing U.S. Hispanic healthcare market. Representing the Company will be COO, Mr. Charles W. Hansen and Co-Chairman and Senior Vice-President, Mr. Raymond Talarico. Additional meetings are scheduled with high level officials in the Chinese government, as well as the United States Department of Commerce trade officials in each city.
Mr. Raymond J. Talarico, Co-Chairman and Senior Vice-President, MEDirect Latino stated, "We are looking forward to participating in Business Mission China and fostering strategic relationships that provide MEDirect with control of our supply chain and the distribution of many of the products we sell, at pricing levels which are very compelling. In essence, by developing products that are culturally specific and demographically targeted to our Hispanic customer, we create competitive barriers in the market as well as build additional value in our Company. MEDirect Latino's goal for the Mission is to reduce cost of goods, increase quality, while developing greater efficiencies for the Company's Medicare Reimbursable model. This will set the pace for future pricing policies that position MEDirect Latino for the Modernization Act of 2003 - Competitive Acquisition Program."
ABOUT MEDIRECT LATINO:
MEDirect Latino (Pink Sheets:MLTO) (www.medirectlatino.org) is the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community. MEDirect Latino is rapidly growing and uniquely positioned to service the Hispanic community in the United States and Puerto Rico. MEDirect is the only company currently positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically due to the disproportionate impact and increasing diagnosis rate of diabetes within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was targeted because of its unique status within the Medicare reimbursement regime and due to its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These and other conditions represent considerable future market potential, MEDirect will scale its model by leveraging its existing client base and infrastructure in introducing new products and services to existing customers as they are identified.
The MEDirect Latino Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=1873
Safe Harbor Disclosure:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.